Clinical trials: sponsored by Celgene
Graft-versus-Host Disease
Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)
The goal of this clinical research study is to learn if Revlimid® (lenalidomide), along with standard-of-care steroid treatment you are already receiving, can help to control Chronic Graft-Versus-Host Disease (cGVHD).
- Trial name
- NCT00675441
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
RATIONALE: Bortezomib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma
- Trial name
- NCT01129180
- Testing
- azacitidine, bortezomib, Correlative studies
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Pierluigi Porcu
Erosive Osteoarthritis of the Hand
Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis
STUDY DESIGN: This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study in 30 patients with erosive osteoarthritis of interphalangeal joints.
- Trial name
- NCT01200472
- Testing
- Apremilast
- Where
- 3 sites in Germany
- Volunteers
- 30 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Chronic Lymphocytic Leukemia
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
The rationale for combining lenalidomide with rituximab derives from preclinical observations suggesting that lenalidomide may enhance the ADCC (antigen-dependent cellular cytotoxicity) triggered by monoclonal antibodies such as…
- Trial name
- LLC-LENAR-08 (NCT01185262)
- Testing
- Lenalidomida and Rituximab
- Where
- 7 sites in Spain
- Volunteers
- 25 people
- Sponsor
- MD Anderson International Spain SA
Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
The purpose of this study is to assess pharmacokinetic and pharmacodynamic characteristics of oral lenalidomide monotherapy administered to patients with Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS).
- Trial name
- NCT00910858
- Testing
- Lenalidomide, Recombinant human erythropoietin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Celgene Corporation
Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
The hypothesis of this study is that lenalidomide can be an effective drug in preventing relapse of MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q after allogeneic HSCT.
- Trial name
- LENAMAINT (NCT00720850)
- Testing
- lenalidomide
- Where
- 7 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Technische Universität Dresden
Breast Cancer
Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer
This trial combines trastuzumab and bevacizumab monoclonal antibodies, with ABI-007 and carboplatin, as neoadjuvant therapy in previously untreated locally advanced breast cancers demonstrating HER2 gene amplification.
- Trial name
- NCT00392392
- Testing
- nab-paclitaxel, Bevacizumab, Trastuzumab
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- SCRI Development Innovations, LLC
Myelodysplastic Syndromes
Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes
The purpose of this study is to find out what dose of lenalidomide is safe to use in combination with decitabine when given in people with myelodysplastic syndrome.
- Trial name
- NCT00828802
- Testing
- Lenalidomide, Decitabine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Leukemia, Lymphocytic, Chronic, B-Cell
Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
The aim of this study is to determine the maximal tolerated dose level of lenalidomide combined with fludarabine/rituximab in the therapy of patients with previously untreated CD20-positive chronic lymphocytic leukemia.
- Trial name
- NCT00738829
- Testing
- Lenalidomide, Fludarabine, Rituximab
- Where
- 7 sites in Austria
- Volunteers
- 45 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Complex Regional Pain Syndrome, Type I
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1
The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Lenalidomide in adult subjects with Complex Regional Pain Syndrome (CRPS) Type 1.
- Trial name
- CRPS-002 (NCT00109772)
- Testing
- lenalidomide
- Where
- 27 sites in United States
- Volunteers
- 184 people
- Sponsor
- Celgene Corporation
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
The goal of this clinical research study is to find out if Revlimid can help to control the disease in patients with relapsed/refractory acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS) with…
- Trial name
- NCT00360672
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Prostatitis, Pelvic Pain
Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain
To determine the efficacy of thalidomide for treatment of the Chronic Pelvic Pain Syndrome (CPPS).
- Trial name
- NCT00301405
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Kenneth Peters, MD
Multiple Myeloma
QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
The primary objective is to evaluate when Revlimid and Dexamethasone treatment extend the time to progression to symptomatic MM in patients with smoldering MM.
- Trial name
- QUIREDEX (NCT00480363)
- Testing
- Maintenance with lower doses of lenalidomide and dexamethasone
- Where
- 13 sites in Spain
- Volunteers
- 120 people
- Sponsor
- PETHEMA Foundation
Gastrointestinal Hemorrhage, Portal Hypertension
Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE
The natural history of cirrhosis has a symptomatic and asymptomatic stage. The symptoms include the development of ascites, hepatic encephalopathy, or variceal bleeding.
- Trial name
- NCT00787436
- Testing
- Thalidomide
- Where
- United States
- Sponsor
- The Cleveland Clinic
Histologically Proven Extranodal NKTcell Lymphoma
A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma
Extranodal NK/T-cell lymphoma is a rare disease entity with aggressive clinical course and poor prognosis. Currently, there is no treatment option for relapsed or refractory extranodal NK/T-cell lymphoma.
- Trial name
- Ro-ENKTL (NCT01913119)
- Testing
- Romidepsin
- Where
- 4 sites in South Korea
- Volunteers
- 16 people
- Sponsor
- Samsung Medical Center
Colorectal Cancer
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.
- Trial name
- NCT01032291
- Testing
- cetuximab, lenalidomide
- Where
- 17 sites in Australia, Belgium and 4 more
- Volunteers
- 51 people
- Sponsor
- Celgene Corporation
Sarcoidosis, Cutaneous Sarcoidosis
The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis
To determine whether CC-10004, a phosphodiesterase inhibitor, is useful in treating chronic cutaneous sarcoidosis.
- Trial name
- NCT00794274
- Testing
- CC-100004
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Cincinnati
Myelodysplastic Syndromes
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
This study is a multi-center, single-arm, open-label study of oral CC-5013 monotherapy administered at a dose of 10 mg daily on Days 1-21 every 28 days (28-day cycles) to red blood cell (RBC) transfusion-dependent subjects with…
- Trial name
- NCT00064974
- Testing
- CC-5013
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 215 people
- Sponsor
- Celgene Corporation
Metastatic Pancreatic Cancer
Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
To evaluate the 6-month overall survival, safety, and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer.
- Trial name
- NCT00837031
- Testing
- Lenalidomide, Gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 72 people
- Sponsor
- SCRI Development Innovations, LLC
Pancreatic Cancer
CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas
Because the activity of CC-4047 addresses numerous mechanisms of carcinoma growth inhibition - including, but not limited to anti-angiogenesis - CC-4047 has been selected for development as part of induction chemotherapy regimens…
- Trial name
- NCT00540579
- Testing
- Pomalidomide, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- SCRI Development Innovations, LLC